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INTRODUCTION
Cancer chemotherapy has been used for more 
than 50 years,1 but clinical antiemetic research 
has, in general, only been actively pursued for 
the past 25 years. With the introduction in the 
late 1970s of cisplatin, the cytostatic with 
the highest emetic potential, nausea and vomiting 
soon became two of the most severe prob-
lems for patients treated with chemotherapy.2 
Chemotherapy-induced nausea and vomiting is 
categorized into the acute and the delayed phases, 
which occur 0–24 h and 24–120 h after initiation 
of chemotherapy, respectively. Antiemetics should 
be given prophylactically and treatment depends 
on the chemotherapy regimens used. A number 
of patient-related risk factors have been defined, 
including female sex and young age. It is also well-
known that patients who experience acute emesis 
have a higher risk of developing delayed emesis 
than those who are completely protected during 
the acute phase. This carry-over effect from the 
acute to the delayed phase should be recognized 
when results from antiemetic trials are inter-
preted. This Review discusses the pathophysiology 
of nausea and vomiting, the development of 
antiemetics, highlights some of the newest anti-
emetics, and finally summarizes recommendations 
from clinical evidence-based guidelines. 
HISTORY OF PATHOPHYSIOLOGY
Although the history of the pathophysiology of 
chemotherapy-induced nausea and vomiting 
goes back more than a hundred years, it is still 
only partly elucidated. The most likely mechanism 
of chemotherapy-induced nausea involves the 
release of emetic transmitters (agonists) such as 
dopamine, serotonin and substance P, which bind 
to different receptors located in areas of the gut 
and the central nervous system. Most antiemetics 
are thought to exert their effect by binding to the 
same receptors (antagonists), thereby preventing 
the emetic stimuli. 
The existence of a vomiting center, which 
is located in the medulla oblongata, was first 
proposed by Thumas in 1892,3 and further 
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explored in 1923 by Hatcher and Weiss,4 who also 
found that the sensory nuclei of the vagi nerves 
are important. Wang and Borison5,6 identified 
the chemoreceptor trigger zone, which is located 
in the area postrema outside the blood–brain 
barrier, and as such is sensitive to both blood-
borne and cerebrospinal fluid-borne emetic 
stimuli. During the next 40 years the existence of 
the chemoreceptor trigger zone was supported 
by some groups,7–9 but questioned by others.10 
Today we don’t consider the vomiting center to 
be a well-defined anatomical area, but to exist 
as interconnecting neural networks penetrating 
into the nucleus of the tractus solitarius.11,12 The 
most important antiemetics are the serotonin 
(5-hydroxytryptamine; 5-HT) 5-HT3-receptor 
antagonists, neurokinin (NK)1-receptor antago-
nists and corticosteroids. An overview of serotonin 
and serotonin receptors and of tachykinins and 
neurokinin receptors is shown in Tables 1 and 2. 
Dopamine and dopamine receptors
Dopamine receptors are divided into five groups 
(D1–D5), but until recently only the D2 recep-
tors were associated with the genesis of emesis. 
Studies now indicate that central D3 receptors are 
involved because the selective D3-receptor agonist, 
7-hydroxy-2-(N,N-di-n-propyl-amino) tetraline 
(7-OH-DPAT), was able to induce emesis in a 
dose-dependent manner in dogs13 and ferrets.14 
Studies of D2-receptor antagonists comprised 
the first antiemetic research and began in the 
1960s.15 Owing to the limited antiemetic activity, 
the adverse effects of some of these compounds 
(e.g. metoclopramide, haloperidol) or the limited 
distribution of these drugs worldwide (e.g. 
metopimazine), these agents are primarily used 
as rescue antiemetics. 
Serotonin and 5-HT receptors
Serotonin was isolated in 1948,16 and 9 years later 
Gaddum and Picarelli identified two pharmaco-
logically different receptors for serotonin, today 
known as the 5-HT2 and 5-HT3 receptors.
17 In 
1979, Peroutka and Snyder provided evidence for 
two binding sites in brain tissue, namely 5-HT1 
and 5-HT2 receptors (Table 1).
18 In 1986, a classifi-
cation system categorized serotonin receptors 
into three main groups, 5-HT1-like, 5-HT2 and 
5-HT3 receptors.
19 Today we know of seven main 
groups20 and several subgroups, the most recently 
discovered being 5-HT3A and 5-HT3B.
21 The 
5-HT3 receptor is a transmitter-gated ion channel 
of the cysteine-loop family, that occurs with 
highest frequency in the gut and in the nucleus 
of the tractus solitarius.22,23 The hypothesis that 
5-HT3-receptor antagonists might be useful as 
antiemetics was based on the results of several 
Table 1 History of serotonin and 5-HT receptors. 
year of 
publication
Identification and development of 5-HT and its receptors references
1948 Isolation of serotonin Rapport et al. (1948)16
1957 Two different receptors for 5-HT described Gaddum and Picarelli (1957)17
1978 Metoclopramide; a weak 5-HT3-RA discovered Fozard and Mobarok ALI 
(1978)24
1979 Identification of two different binding sites for 5-HT in brain tissue Peroutka and Snyder (1979)18
1984 First demonstration of a selective 5-HT3-RA—MDL 72222 Fozard (1984)
26
1984–1987 5-HT3 receptors demonstrated in abdominal visceral afferent 
neurons and in the CNS
Miner and Sanger (1986)27
1986 MDL 72222/ICS 205-930 effective against cisplatin-induced 
emesis
Costall et al. (1986)28
1986 Classification of three serotonin receptor groups Bradley et al. (1986)19
1987 First clinical trial of a 5-HT3-RA with antiemetic effect Leibundgut and Lancranjan 
(1987)29
1987–1990 Discovery that the highest number of 5-HT3 receptors  
is in the NTS
Kilpatrick et al. (1987)22
Pratt et al. (1990)23
1994 Reclassification of serotonin receptors into seven groups Hoyer et al. (1994)20
2005 5-HT3-receptor subunits cloned Barrera et al. (2005)
21
Abbreviations: CNS, central nervous system; 5-HT, 5-hydroxytryptamine (serotonin); 5-HT3-RA, 5-hydroxytryptamine3-receptor 
antagonist; NTS, nucleus of the solitary tract. 
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studies, including the findings that metoclo-
pramide is a weak 5-HT3-receptor antagonist,
24 
and that high-dose metoclopramide is effec-
tive against cisplatin-induced emesis.25 These 
discoveries led to the development of selective 
5-HT3-receptor antagonists,
26 the demonstra-
tion of antiemetic effect in animal models,27,28 
and the publication of the first clinical study of an 
5-HT3-receptor antagonist in 1987.
29
Tachykinins and neurokinin receptors
Substance P was isolated in 193130 but not puri-
fied and sequenced until 1970.31 Tachykinins 
are a family of peptides of small and medium 
size. The receptors for the tachykinins, the NK-
receptors, have been cloned and identified as 
G-protein-coupled receptors; substance P is the 
preferred tachykinin at NK1-receptors. The first 
selective NK1-receptor antagonist was developed 
in 1981,32 but the potential of NK1-receptor 
antagonists as antiemetics was not realized until 
the development of a non-peptide NK1-receptor 
antagonist 10 years later.33 In order to exert their 
antiemetic effects the NK1-receptor antagonists 
need to cross the blood–brain barrier, and it was 
this requirement that led to the delay in their use 
as antiemetics. The first indication that emesis 
might have a tachykinin component came from 
a study demonstrating that a non-peptide NK1-
receptor antagonist attenuated cisplatin-induced 
emesis in the ferret.34 A number of studies using 
different animal models have shown that NK1-
receptor antagonists have a broad-spectrum 
antiemetic profile including effect against emesis 
induced by chemotherapy, apomorphine, lopera-
mide, motion, copper sulfate, ipecacuanha and 
nicotine. The first clinical study with one of these 
components was published in 1997.35 
Other transmitters and receptors
Other transmitters that are involved in the emetic 
reflex arch include histamine, acetylcholine, 
endorphins, gamma-aminobutyric acid and 
cannabinoids. Histamine and acetylcholine are 
important in the induction of motion sickness. 
Consequently, studies investigating antihistamine 
and anticholinergics showed little36 or no effect37 
against chemotherapy-induced nausea and 
vomiting. The only other transmitter known to 
be involved in chemotherapy-induced emesis 
is the cannabinoid (CB)1-receptor. In contrast 
to other antiemetics, the cannabinoids exert 
antiemetic effects by agonism at CB1 receptors. 
Studies from the 1970s and early 1980s showed 
that agents like dronabinol and nabilone have 
antiemetic effects in patients receiving moder-
ately emetogenic chemotherapy, but their use is 
restricted because of associated adverse events, 
particular in elderly patients.38
HISTORY OF ANTIeMeTIC THeRAPY
Low-dose dopamine (D2)-receptor 
antagonists
The development of antiemetic therapy is 
summarized in Table 3. A few trials investigating 
low doses of dopamine D2-receptor antagonists 
Table 2 History of tachykinins and neurokinin receptors. 
year of 
publication
Identification of peptides and compounds references
1931 Isolation of substance P Von Euler and Gaddum (1931)30
1970 Substance P purified and structure revealed Chang and Leeman (1970)31 
1981 First NK1-receptor antagonist demonstrated Leander et al. (1981)
32
1983 NKA and NKB isolated Kangawa et al. (1983)92
Kimura et al. (1983)93
1985 NPK isolated Tatemoto et al. (1985)94
1988 NPγ isolated Kage et al. (1988)95
1991 First non-peptide NK1-receptor antagonist (CP 96,345) Snider et al. (1991)
33
1993 Substance P, NKA and NKB shown to be present in CNS and PNS Maggi et al. (1993)96
1993 Study suggests that emesis might have a tachykinin component Tattersall et al. (1993)34
1997 First clinical trial of a NK1-RA with antiemetic effect Kris et al. (1997)
35
Abbreviations: CNS, central nervous system; NK1-RA, neurokinin 1-receptor antagonist; NKA, neurokinin A; NKB; neurokinin B; 
NPγ, neuropeptide γ; PNS, peripheral nervous system.
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showed modest or no effect against different 
kinds of chemotherapy.15,25 Some of the pheno-
thiazines, (e.g. metopimazine and the substituted 
benzamide, metoclopramide) showed an indica-
tion of a dose-dependent effect, and higher doses 
of these drugs were investigated.38 
Corticosteroids
Baker and co-workers published the first 
randomized trial comparing dexamethasone 
with placebo.39 They found that the antiemetic 
effects of 10 mg of intramuscular dexamethasone 
were significantly superior to placebo in patients 
receiving various kinds of non-cisplatin chemo-
therapy. This study led to the initiation of a large 
number of clinical trials investigating different 
corticosteroids, which concluded that, when 
given as single agents, corticosteroids have an 
antiemetic effect in patients receiving moderately 
emetogenic chemotherapy, but are less effective 
against cisplatin-induced emesis.38,40 Subsequent 
studies showed that corticosteroids increase the 
effect of other antiemetics such as low-dose and 
high-dose metoclopramide,41 5-HT3-receptor 
antagonists42,43 and the NK1-receptor antagonist, 
aprepitant (Table 4). Studies have now verified 
that dexamethasone is one of the most potent 
antiemetics for the prevention of delayed nausea 
and vomiting.44,45
High-dose metoclopramide
One of the most frequently quoted articles in 
the antiemetic literature is by Gralla et al., which 
demonstrates that the antiemetic effects of high-
dose metoclopramide are superior to those of 
placebo and prochlorperazine.25 The median 
number of emetic episodes per patient receiving 
cisplatin-based chemotherapy was reduced from 
10.5 in the placebo arm and 12 in the prochlor-
perazine arm to 1–1.5 with high-dose meto-
clopramide. These findings showed that patients 
receiving cisplatin-based chemotherapy could 
be offered an effective antiemetic therapy. Other 
studies tried to fine-tune the metoclopramide 
regimen, and revealed that although high-dose 
metoclopramide is effective, it causes extra-
pyramidal reactions in a number of patients and 
only 40% of patients are completely protected 
from emesis in the first 24 h after cisplatin adminis-
tration. Agents such as the antihistamine diphen-
hydramine, the benzodiazepine lorazepam or the 
anticholinergic biperidene, were all able to prevent 
the extrapyramidal reactions associated with 
metoclopramide, but did not significantly improve 
antiemetic effect.46 As mentioned earlier, cortico-
steroids significantly improve the antiemetic effect 
of high-dose metoclopramide in cisplatin-induced 
emesis,41 and a three-drug combination of high-
dose metoclopramide, a corticosteroid and either 
Table 3 History of antiemetic therapy.
year of 
publication
Identification of antiemetic therapies references
1979 Corticosteroids demonstrated as superior to placebo Baker et al. (1979)39
1981 Hd-MCP demonstrated as effective Gralla et al. (1981)25
1984 A corticosteroid demonstrated to improve effect of hd-MCP Allan et al. (1984)41
1987 First clinical trial with a 5-HT3-RA Leibundgut and Lancranjan 
(1987)29
1991 A corticosteroid demonstrated to improve the effect  
of 5-HT3-RAs (HEC)
Roila et al. (1991)42
1993 A dopamine antagonist demonstrated to improve the effect  
of a 5-HT3-RA
Herrstedt et al. (1993)59
1995 A corticosteroid demonstrated to improve the effect  
of 5-HT3-RAs (MEC)
Italian Group for Antiemetic 
Research (1995)43
1997 First clinical trial with a NK1-RA Kris et al. (1997)
35
2003 NK1-RA demonstrated to improve effect of 5-HT3-RA  
plus corticosteroid (HEC)
Poli-Bigelli et al. (2003)71
Hesketh et al. (2003)72
2005 NK1-RA demonstrated to improve effect of 5-HT3-RA  
plus corticosteroid (MEC)
Warr et al. (2005)73
Abbreviations: hd-MCP, high-dose metoclopramide; HEC, highly emetogenic chemotherapy; 5-HT3-RA, 5-hydroxytryptamine3-
receptor antagonist; MEC, moderately emetogenic chemotherapy; NK1-RA; neurokinin 1-receptor antagonist.
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lorazepam or diphenhydramine was considered 
the standard antiemetic regimen for patients 
receiving cisplatin-based chemotherapy until the 
development of the serotonin antagonists.46
5-HT3-receptor antagonists
After the publication of the first studies with a 
5-HT3-receptor antagonist,
29,47 the develop-
ment of these agents was accelerated. The first 
two agents that were marketed, at the beginning 
of the 1990s, were ondansetron and granisetron, 
followed by tropisetron, and dolasetron, and 
most recently palonosetron in 2003. Two other 
agents ramosetron and azasetron are marketed in 
Japan only. The clinical development of ondan-
setron and granisetron followed two different 
strategies. Ondansetron was compared with the 
single agents most effective in patients receiving 
cisplatin-based and non-cisplatin chemotherapy. 
Studies showed that ondansetron was signifi-
cantly superior to high-dose metoclopramide in 
the prevention of cisplatin-induced emesis,48–50 
but no major differences in the protection against 
nausea were observed. Other studies compared 
metoclopramide51–53 or dexamethasone54 with 
ondansetron in patients receiving different 
types of non-cisplatin chemotherapy, primarily 
cyclophosphamide plus an anthracycline. In two 
studies, ondansetron was significantly superior 
to metoclopramide in the protection from both 
nausea and vomiting,51,52 whereas in the third 
study no significant differences in the degree 
of protection were observed.53 In the study 
comparing dexamethasone and ondansetron, 
both agents offered equal protection against 
nausea and vomiting during the first 24 h after 
the initiation of chemotherapy.54 
Warr et al. investigated granisetron in two 
studies and found that granisetron was as effective 
as the combination of high-dose metoclopramide 
and dexamethasone in patients treated with 
cisplatin,55 and superior to dexamethasone plus 
prochlorperazine in patients receiving moder-
ately emetogenic chemotherapy.56 Although 
many of the aforementioned studies followed 
patients for 3–5 days, all studies were designed 
to evaluate acute nausea and vomiting. The 
efficacy of the serotonin antagonists against 
delayed emesis is much less pronounced,57 and 
dexamethasone and/or the NK1-receptor antago-
nist, aprepitant, are recommended as first choice 
antiemetics against delayed emesis.44,45
A large number of trials have compared two or 
three of the serotonin antagonists. There seem to 
be no major differences in effect or safety between 
these agents, with mild headache and constipa-
tion being the two most frequently reported side 
effects. In the setting of highly emetogenic42,58 or 
moderately emetogenic43 chemotherapy, protec-
tion from acute emesis with serotonin antagonists 
is improved by the addition of dexamethasone. 
A few studies have shown that the dopamine 
antagonist, metopimazine, can improve the effect 
of ondansetron,59,60 but this agent is not avail-
able in the US, Canada or Japan. For more than 
10 years, the combination of a serotonin antago-
nist plus a corticosteroid was the recommended 
standard antiemetic regimen in patients receiving 
Table 4 Phase III trials with the neurokinin 1-receptor antagonist aprepitant.
reference design Number  
of patients
Chemotherapy 
(mg/m2)
Antiemetic regimens day 1
acutea 
(%)
days 2–5
delayeda 
(%)
days 1–5
totala 
(%)
Poli-Bigelli  
et al. (2003)71
R, DB, 
2P
569 CIS ≥70 + others OND day 1 + DEX days 1–4 68.4 46.8 43.3
OND day 1 + DEX days1–4 + APR days 1–3 82.8 67.7 62.7
Hesketh  
et al. (2003)72
R, DB, 
2P
530 CIS ≥70 + others OND day 1 + DEX day 1–4 78.1 55.8 52.3
OND day 1 + DEX days 1–4 + APR days 1–3 89.2 75.4 72.7
Schmoll et al. 
(2006)74
R, DB, 
2P
489 CIS ≥70 + others OND days 1–4 + DEX days 1–4 79.3 63.1 60.6
OND day 1 + DEX days 1–4 + APR days 1–3 87.7 74.1 72
Warr et al. 
(2005)73
R, DB, 
2P
857 C alone 750–1,500 OND day 1 + DEX day 1 all patients – – –
or A ≤60 + C 500–1,500 + OND day 2–3 69 49 42
or E ≤100 + C 500–1,500 + APR day 1–3 76 55 51
aPercentage of patients with no emesis and with no use of rescue antiemetics. Abbreviations: 2P, parallel, 2-arm trial; A, doxorubicin; APR, 
aprepitant; CIS, cisplatin; C, cyclophosphamide; DB, double-blind; DEX, dexamethasone; E, epirubicin; OND, ondansetron; R, randomized. 
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moderately or highly emetogenic chemotherapy,61 
but the advent of new antiemetics have changed 
this picture.
New ANTIeMeTICS
Palonosetron
Two new antiemetics were marketed in 2003, the 
serotonin antagonist palonosetron, and aprepi-
tant, the first of a new class of antiemetics—the 
NK1-receptor antagonists. Palonosetron has 
been studied in five phase I, one phase II and 
three phase III trials. In addition, a number of 
small post-marketing trials have recently been 
published. Palonosetron has a strong and selec-
tive binding affinity for 5-HT3-receptors, and 
a half-life of around 40 h, compared with less 
than 10 h for the other 5-HT3-receptor antago-
nists.62 Phase I and II trials confirmed the safety 
of palonosetron, noting the same adverse effects 
observed with the other agents of this class. 
Two randomized, double-blind trials compared 
palonosetron with ondansetron and dolasetron in 
patients treated with chemotherapy of a moderate 
emetogenic potential.63,64 Gralla and coauthors 
compared single intravenous doses of palono-
setron (0.25 mg and 0.75 mg) with ondansetron 
(32 mg),63 and found that palonosetron was supe-
rior to ondansetron in the prophylaxis of both 
acute and delayed nausea and vomiting. Eisenberg 
et al. compared palonosetron with a single intra-
venous dose of 100 mg dolasetron using the same 
design and doses of palonosetron.64 They found 
equal efficacy against acute nausea and vomiting, 
but palonosetron was superior against delayed 
symptoms. Aapro et al. found that 0.25 mg 
palonosetron was as effective as ondansetron in 
the prevention of nausea and vomiting induced 
by highly emetogenic, primarily cisplatin- 
 based, chemotherapy.65 The interpretation of the 
results of these studies has, however, been inten-
sively debated because of the trial design. All 
trials used a non-inferiority design and included 
chemotherapy-naive patients as well as patients 
who had previously received chemotherapy. 
Furthermore, the recommended prophylaxis 
included dexamethasone, but in each of the three 
trials only 0%,63 5%64 and 67%65 of the patients 
received dexamethasone. The studies did not use 
the optimum design for investigation of delayed 
symptoms because patients received different 
antiemetics against acute symptoms, and anti-
emetics were given only on day 1. Finally, patients 
receiving low-dose cisplatin were included in the 
moderately emetogenic chemotherapy studies, 
even though cisplatin is considered highly emeto-
genic at any dose. Despite these limitations, the 
data strongly indicate that palonosetron is supe-
rior to ondansetron and dolasetron. As a conse-
quence of the difficult interpretation, the US FDA 
has approved palonosetron for the prevention of 
both acute and delayed nausea and vomiting in 
patients treated with moderately emetogenic 
chemotherapy and for the prevention of acute 
emesis in patients treated with highly emeto-
genic chemotherapy. By contrast the European 
Agency for the Evaluation of Medicinal Products 
has approved palonosetron for the prevention of 
acute symptoms only.
Aprepitant
There are no published phase I trials of aprepitant, 
but five phase II trials66–70 and three phase III 
trials have been published.71–73 A large post-
marketing randomized study74 and a few small 
studies have also been published recently. The 
phase II trials were randomized and double-
blind, enrolling between 53 and 376 patients 
receiving cisplatin-based chemotherapy. The 
studies examined the efficacy of aprepitant in 
the prevention of acute nausea and vomiting from 
cisplatin-based chemotherapy. The trials clearly 
demonstrated that aprepitant as a single agent66 
or in combination with dexamethasone68,69 is 
inferior to ondansetron66,68 and granisetron69 
but increases the efficacy of granisetron plus 
dexamethasone67,69 and ondansetron plus dexa-
methasone regimens.70 In all five studies, aprepi-
tant was active in the prophylaxis of delayed 
(day 2–5) nausea and vomiting. We know from 
several previous studies, that patients who vomit 
on the day of chemotherapy have a higher risk 
of delayed emesis. It is, therefore, noteworthy 
that in the three studies in which the aprepitant- 
based regimen was inferior to the serotonin 
antagonist-based regimen on day 1, the aprepitant- 
 based regimen was superior in the delayed 
phase.66,68,69 Four of the phase II trials used an 
intravenous prodrug66,68 or higher dose of oral 
aprepitant67,70 than was used in phase III trials. 
The reduction of the aprepitant dose in phase 
III was because of results from a fifth phase II 
trial, which showed that aprepitant increased the 
bioavailability of dexamethasone via interactions 
with the CYP3A4 enzymes.70 Furthermore, the 
number of patients with infection was higher 
in the aprepitant arm than in the comparative 
arm. In conclusion, phase II studies revealed 
that aprepitant is not a substitute for a serotonin 
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antagonist in the prevention of acute nausea and 
vomiting, but has utility as an additive to the 
antiemetic combination of serotonin antagonist 
plus dexamethasone. Furthermore, they demon-
strated that aprepitant is effective against delayed 
symptoms as a single agent and recommended 
that the schedule for phase III studies should be 
125 mg on day 1, followed by 80 mg on days 2 and 
3 given as single oral doses. They also concluded 
that in phase III studies, the dose of dexametha-
sone used in the aprepitant-based regimen should 
be reduced to 50–60% of that used in the control 
arm. Special attention to the number of patients 
with infection in phase III studies was also recom-
mended. The optimum treatment duration was 
not addressed in phase II studies. Two studies 
showed that there was no significant difference 
between 1-day and 5-day regimens for aprepitant 
administration, in terms of efficacy of antiemetic 
effect.67,75 The 3-day regimen for phase III was, 
therefore, arbitrarily chosen.
Phase III trials were published between 2003 
and 2005, and a large post-marketing study was 
published in 2006 (Table 4).74 In three studies, 
patients received cisplatin-based chemo-
therapy, and in one study patients received a 
combination of cyclophosphamide plus an 
anthracycline. All studies used a randomized, 
double-blind, placebo-controlled design.71–74 
Two of the studies71,72 used an identical 
design and compared the effect of single intra-
venous doses of 32 mg ondansetron plus 20 mg 
p.o. dexamethasone on day 1 followed by 2 × 8 mg 
dexamethasone on days 2–4, with single doses 
of intravenous 32 mg ondansetron plus 12 mg 
p.o. dexamethasone plus 125 mg p.o. aprepitant 
on day 1. This latter regimen was followed by a 
single oral dose of 8 mg dexamethasone on days 
2–4 plus a single oral dose of aprepitant 80 mg 
on days 2–3. The primary efficacy parameter was 
complete response (i.e. defined as “no emesis and 
no need for rescue antiemetics”) during the first 
5 days after cisplatin treatment. The third study 
used the same design and dose schedule; however, 
patients in the control arm also received ondan-
setron 2 × 8 mg p.o. for delayed emesis protec-
tion (days 2–4).74 The number of patients with 
a complete response in the control regimens of 
these three trials were 43%,71 52%72 and 61%,74 
respectively, compared with 63%,71 73%72 and 
72%74 in the aprepitant-based regimens. The 
difference in complete response of 11–21% 
was statistically significant. In only one study was 
a statistically significant difference in protection 
from nausea (no nausea days 1–5) obtained 
with the aprepitant-based regimen (49% versus 
39%, P <0.05).71
In the study including patients receiving cyclo-
phosphamide plus an anthracycline,73 99% were 
women with breast cancer treated in the adjuvant 
setting or for metastatic disease. Patients were 
randomized to an oral control regimen consisting 
of 2 × 8 mg ondansetron plus 20 mg dexa-
methasone on day 1, followed by ondansetron 
2 × 8 mg on days 2–3 or to an oral aprepitant- 
 based regimen of 2 × 8 mg ondansetron with 
12 mg dexamethasone plus 125 mg aprepitant 
on day 1, followed by 80 mg aprepitant on days 
2–3. The aprepitant-based regimen resulted in 
a 9% improvement in the number of patients 
achieving a complete response during days 1–5 
(51% versus 42%, P = 0.015), and in a 17% incre-
ment in the number of patients with no emesis 
on days 1–5 (76% versus 59%, P <0.001). No 
significant differences in the protection from 
nausea were seen. The phase III studies demon-
strated that in patients receiving cisplatin-based 
or cyclophosphamide/anthracycline chemo-
therapy, aprepitant increases the proportion 
who receive complete response by 9–21%. The 
benefit is primarily attributable to an approxi-
mately 20% reduction in the number of emetic 
episodes; the reduction in nausea seems to be 
limited. The advantage of the aprepitant-based 
regimen was maintained during 4–6 cycles 
of chemotherapy.76,77 
Aprepitant is a CYP3A4 substrate and the 
effects of aprepitant on drugs that inhibit (i.e. 
ketoconazole, diltiazem) or induce (i.e. rifampin) 
CYP3A4 have, therefore, been investigated. 
Caution is advised when administering aprepi-
tant with strong inhibitors of CYP3A4. The 
bioavailability of oral CYP3A4 substrates (e.g. 
midazolam and other benzodiazepines) may 
increase when coadministered with aprepitant. 
Rifampin is a strong inducer of CYP3A4 and 
lowers the area under the receiver operating 
characteristic curve of aprepitant significantly 
compared with administration of aprepi-
tant alone; coadministration might, therefore, 
decrease the antiemetic effect of aprepitant. 
Aprepitant is also an inducer of CYP2C9 and 
could result in lower plasma concentrations 
of drugs metabolized by this enzyme. This 
effect of aprepitant administration could be of 
clinical significance for drugs metabolized by 
CYP2C9 that have a narrow therapeutic index 
(e.g. warfarin, phenytoin). A study showed that 
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aprepitant has no effect on docetaxel pharmaco-
kinetics.78 This finding is important because 
docetaxel is primarily metabolized by CYP3A4. 
Apart from the interaction between aprepitant 
and oral dexamethasone, no clinically relevant 
interactions between aprepitant and other anti-
emetics have been described. Despite these poten-
tial interaction risks, the safety of aprepitant was 
confirmed in phase III studies: no association 
was found between aprepitant administration 
and incidence of febrile neutropenia.
POTeNTIAL New ANTIeMeTICS
Casopitant and other NK1-receptor 
antagonists
Casopitant has demonstrated antiemetic activity 
in patients receiving moderately79 and highly80 
emetogenic chemotherapy, and is now in phase 
III clinical testing. SCH-619734 is being investi-
gated in phase II trials, and other agents such as 
netupitant, are in earlier clinical development. 
Olanzapine
Olanzapine is an antipsychotic that blocks several 
receptors such as dopamine, serotonin, muscarine 
cholinergic, adrenergic and histamine receptors. It 
has been investigated in phase I and II trials. The 
most recent trial demonstrated exceptionally high 
complete protection rates from both acute and 
delayed nausea and vomiting using a regimen that 
comprised palonosetron (day 1), dexamethasone 
(day 1) and olanzapine (days 1–4).81 
Other agents
The benzodiazepine midazolam is effective in 
prevention of postoperative vomiting. A phase II 
trial reported that midazolam given in combina-
tion with granisetron and dexamethasone was 
effective in the treatment of acute nausea and 
vomiting after treatment with highly emeto-
genic chemotherapy in patients with vomiting 
refractory to antiemetic prophylaxis with grani-
setron and dexamethasone.82 Another potential 
antiemetic, ghrelin, is a peptide secreted by the 
gastric mucosa, which stimulates gastrointestinal 
motility, protects the gastric mucosa and is able to 
stimulate appetite in humans. In a recent trial in 
ferrets, ghrelin was able to reduce the number of 
vomiting events induced by cisplatin.83
evIDeNCe-BASeD GUIDeLINeS
Several international societies and groups have 
developed evidence-based antiemetic guide-
lines, including the Multinational Association 
of Supportive Care in Cancer (MASCC),84 
ASCO85and the European Society for Medical 
Oncology. The National Comprehensive Cancer 
Network (NCCN) has developed guidelines 
on the basis of the knowledge of US opinion 
leaders. The recommendations by MASCC, ASCO 
and the European Society for Medical Oncology 
are generally in agreement. MASCC developed 
their first set of evidence-based guidelines for 
chemotherapy induced nausea and vomiting in 
1997.61 The topics to be included in the MASCC 
guidelines were selected on the basis of a question-
naire distributed to 118 experts in 31 countries.86 
From this process, eight main topics were identi-
fied for discussion at a subsequent consensus 
conference. Presentations reviewing specific 
antiemetic therapies were given by experts and 
discussed among the 300 participants at the 
consensus conference. The expert panel primarily 
comprised physicians, but two statisticians and 
a physiologist were also included. The MASCC 
guidelines state the level of scientific confidence 
and the extent of consensus among the experts. 
The second MASCC consensus conference was in 
2004, during which 23 experts representing nine 
different organizations updated the 1997 recom-
mendations and developed the setup for future 
updates. The latest version of these recommen-
dations was published in 2006,84 but the most 
recent update is available on the MASCC website 
(www.mascc.org). MASCC has divided cyto-
toxic agents into four emetic risk groups and has 
provided recommendations for the prophylaxis 
of acute and delayed nausea and vomiting for 
each group, as shown in Box 1.
The recommendations given in the MASCC 
and ASCO guidelines are almost identical. 
One exception is the recommendation for 
the prophylaxis of delayed emesis in patients 
receiving a combination of cyclophosphamide 
plus an anthracycline. The MASCC guidelines84 
recommend using dexamethasone or aprepi-
tant, whereas the ASCO guidelines85 recom-
mend aprepitant alone. Both recommendations 
can be justified. No trial has compared these 
two antiemetics in this setting, so the MASCC 
recommendation is reasonable, on the basis of 
available evidence. Nonetheless, it seems rational 
to continue with aprepitant on days 2 and 3 in 
patients who received aprepitant on day 1.
GUIDeLINeS APPLIeD IN PRACTICe
Clinical practice guidelines can be of consider-
able use and can enable physicians to prescribe 
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the optimum prophylaxis and therapy. There 
are, however, a number of potential barriers and 
limitations to their use. Some antiemetic topics 
are very well investigated whereas others have 
been addressed in only a limited number of trials 
that often include only a small number of 
patients. Consequently, antiemetic guidelines 
are highly evidence-based for the prophylaxis 
of acute cisplatin-induced (i.e. highly emeto-
genic) nausea and vomiting, whereas the recom-
mendations for prophylaxis of delayed nausea 
and vomiting induced by highly or moderately 
emetogenic chemotherapy are made on the basis 
of a lower level of scientific evidence. 
Several studies have shown that the implemen-
tation of antiemetic guidelines is difficult. 
Nonetheless, the effort involved in their 
implementation is worthwhile because patients 
who receive evidence-based antiemetic therapy, 
do better87 and effective antiemetic therapy can 
be cost-effective.88 Barriers to execution of anti-
emetic guidelines include reimbursement policy, 
linguistic problems, the fact that new drugs are 
expensive and not available in all countries, 
and underestimation of the magnitude of the 
problem of preventing chemotherapy-induced 
nausea and vomiting.89 
CONCLUSIONS
The combination of ondansetron, dexametha-
sone and aprepitant is able to protect 66–78% 
of patients from emesis and 48–49% from 
nausea during the first cycle of cisplatin-based 
chemotherapy.72,73,75 In women receiving cyclo-
phosphamide/anthracycline-based chemotherapy 
for breast cancer, the corresponding figures 
are 76% and 33%.74 In a recent phase II study 
comprising 58 patients who received moder-
ately emetogenic chemotherapy, palonosetron in 
combination with aprepitant and dexamethasone 
completely protected 91% of patients from emesis 
and 52% from nausea.90
Grunberg et al. published preliminary results 
from a phase II study investigating antiemetic 
therapy in patients with solid tumors who 
received cyclophosphamide and/or anthracycline 
for the first time. Patients received a 1-day three-
drug antiemetic regimen of single doses of intra-
venous palonosetron and p.o. dexamethasone 
and aprepitant. None of the 15 patients vomited 
during the first 5 days after chemotherapy, none 
reported significant acute nausea, and only 
47% reported significant delayed nausea.91 
Although the results from these phase II studies 
are very promising, the use of palonosetron, aprepi-
tant and dexamethasone should be validated 
in large randomized studies. 
New antiemetics have been highly successful 
in the prophylaxis of emesis, but are less effec-
tive in the prevention of nausea. There is, there-
fore, a particular interest in initiating trials to 
investigate agents with potential anti-nausea 
effect, such as olanzapine. Guidelines such as the 
MASCC antiemetic guidelines are only useful if 
they are continuously updated and implemented 
in the daily clinic. To encourage implementation, 
the MASCC guidelines have been translated into 
several languages, are updated every 6 months (as 
new data arise), and are always accessible on the 
MASCC website.
Box 1 Four emetic risk groups as categorized by 
the Multinational Association of Supportive Care 
in Cancer.
High emetic risk group (more than 90% risk)
Includes cisplatin, dacarbazine and high-dose 
cyclophosphamide (≥1,500 mg/m2)
■ Acute: serotonin antagonist plus dexamethasone 
plus aprepitant
■ Delayed: aprepitant days 2–3 plus 
dexamethasone days 2–3 (or 2–4)
Moderate emetic risk group (30–90% risk)
Includes cyclophosphamide (<1,500 mg/m2), 
anthracyclines, oxaliplatin and carboplatin
■ Acute: serotonin antagonist plus dexamethasone
■ Delayed: dexamethasone days 2–3, if there 
is a risk of delayed nausea and vomiting; 
this is rarely the case for oral cytotoxins, 
such as temozolomide. If a corticosteroid is 
contraindicated, a serotonin antagonist can be 
used instead
■ Patients receiving a combination of 
cyclophosphamide plus an anthracycline 
should receive acute emesis protection as 
recommended for the high-emetic-risk group, 
and delayed emesis protection with aprepitant  
or dexamethasone days 2–3
Low emetic risk group (10–30% risk)
Includes topotecan, gemcitabine, taxanes, 
capecitabine and trastuzumab
■ Acute: low dose of dexamethasone
■ Delayed: no routine prophylaxis
Minimal emetic risk group (less than 10% risk)
Includes bleomycin, vinca-alkaloids and bevacizumab
■ Acute and delayed: no routine prophylaxis
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KeY POINTS 
■ Although the pathophysiology of nausea and 
vomiting is still not completely elucidated, 
the increased understanding of the basic 
mechanisms has advanced the clinical 
development of antiemetics
■ Corticosteroids are useful antiemetics; recently, 
the development of serotonin antagonists and 
the neurokinin antagonist, aprepitant, have 
resulted in a significant decrease in the number 
of vomiting episodes experienced by patients 
receiving emetogenic chemotherapy 
■ Treatment of the nausea associated with 
emetogenic chemotherapy is still a major 
problem
■ Evidence-based guidelines for antiemetic 
treatment have been developed and are 
updated on a regular basis; implementation of 
these guidelines should be encouraged
■ Promising results from phase II studies, of 
dexamethasone plus different two-drug 
combinations of the new serotonin antagonist, 
palonosetron, the neurokinin antagonist, 
aprepitant, and the antipsychotic agent, 
olanzapine, require verification in large 
randomized trials
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